O'Reilly, Terence <br/><br/>
Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Jan 2011 
 - 193-200 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-010-1307-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cell Line, Tumor<br/>Dose-Response Relationship, Drug<br/>Drug Synergism<br/>Everolimus<br/>Female<br/>Mechanistic Target of Rapamycin Complex 1<br/>Melanoma, Experimental--drug therapy<br/>Mice<br/>Mice, Inbred C57BL<br/>Models, Biological<br/>Multiprotein Complexes<br/>Neoplasm Metastasis<br/>Phthalazines--administration & dosage<br/>Proteins--antagonists & inhibitors<br/>Pyridines--administration & dosage<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors<br/>Sirolimus--administration & dosage<br/>TOR Serine-Threonine Kinases